MedTrace Logo

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

NCT02868892 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-11-02

Study results available
· View outcomes & findings →

Summary

Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.

Conditions

  • Adenocarcinoma of the Cervix
  • Adenosquamous Cell Carcinoma of the Cervix

Interventions

DRUG

Pemetrexed

Pemetrexed 500 mg/m2

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • John Farley, MD · Western Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868892 on ClinicalTrials.gov